Risk of major congenital malformations and heart defects in pregnancies exposed ...

연구 요약

Risk of major congenital malformations and heart defects in pregnancies exposed to first-trimester drugs for depression and co-medications.

Journal of psychopharmacology (Oxford, England) 학술지에 발표된 이 연구는 Østergaard Thunbo M, Vendelbo JH, Kolding L 외 연구팀이 수행하였습니다.

이 연구는 'Risk of major congenital malformations and heart defects in pregnancies exposed to first-trimester drugs for depression and co-medications.'에 대한 과학적 분석을 제공합니다.

핵심 내용

INTRODUCTION: Managing depression during pregnancy requires balancing maternal health and fetal safety. As drugs for depression are often used alongside other medications, understanding if these combinations relate to teratogenic risks is important. This study explored patterns of major congenital malformations (MCMs), including congenital heart defects (CHDs), following first-trimester drugs for depression, alone, or with co-medications. METHODS: Using Danish national registry data, we analyzed 674,154 pregnancies, of which 2.2% were exposed to first-trimester drugs for depression. We compared MCMs and CHD occurrences in pregnancies exposed to these drugs, alone or with co-medications, to nonexposed pregnancies and generated estimates to explore potential associations and interactions. RESULTS: Exploratory assessments suggested that overall MCM risk among pregnancies exposed to drugs for depression was similar to nonexposed pregnancies (adjusted odds ratio (95% confidence interval): 1.05 (0.96-1.15)), while CHD risk appeared higher (1.26 (1.08-1.47). Certain co-medications showed signals warranting further study, including possible increases in MCM risk with antihistamines (1.64 (1.14-2.28)) and levothyroxine (1.72 (1.12-2.53)) and a potential decrease with opioids (0.51 (0.27-0.86). For CHDs, drugs for psychosis (1.67 (1.01-2.60)), nonsteroidal anti-inflammatory/antirheumatic medications (2.07 (1.23-3.25)), topical corticosteroid (2.07 (1.02-3.71)), and progesterone (2.01 (1.06-3.45)) showed patterns potentially indicating elevated risk. CONCLUSION: This study provides exploratory insights into how first-trimester use of drugs for depression, alone or with selected co-medications, may relate to MCM and CHD patterns. These findings suggest potential interactions but could also result from confounding or chance. Further research is needed to support clinical decision-making.

일반인을 위한 해석

구체적인 실천 사항은 담당 의사 또는 약사와 상담하시기 바랍니다.

실천 사항

• 현재 복용 중인 약물이나 영양제에 대해 궁금한 점이 있다면 담당 의사 또는 약사와 상담하시기 바랍니다
• 약물이나 영양제의 용법·용량을 임의로 변경하지 마세요
• 이상 반응이 나타나면 즉시 전문가에게 문의하세요

의사/약사의 전문적 판단을 대체하지 않습니다 (PMID: 41622509)